Embecta Corp.

# Signal Note: Deerfield Initiates $32.7M Position in Embecta Deerfield's entry into EMBC (2.75M shares) signals conviction in the diabetes device market, where Embecta maintains leadership in insulin delivery and infusion sets. The position timing aligns with Embecta's pursuit of integrated connected-device solutions and potential M&A consolidation in the $15B+ global insulin delivery market. Watch for upcoming earnings/guidance and any announcements on next-gen CGM integration or geographic expansion as near-term catalysts.